Repligen Corporation

NasdaqGS:RGEN Rapport sur les actions

Capitalisation boursière : US$8.4b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Repligen Croissance future

Future contrôle des critères 4/6

Repligen devrait augmenter ses bénéfices et son chiffre d'affaires de 46.2% et de 13.8% par an respectivement. Le BPA devrait croître de de 46.8% par an. Le rendement des capitaux propres devrait être 4.9% dans 3 ans.

Informations clés

46.2%

Taux de croissance des bénéfices

46.8%

Taux de croissance du BPA

Life Sciences croissance des bénéfices18.1%
Taux de croissance des recettes13.8%
Rendement futur des capitaux propres4.9%
Couverture par les analystes

Good

Dernière mise à jour16 Aug 2024

Mises à jour récentes de la croissance future

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Jul 31
Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Jul 15
We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Repligen: Strong Filtration Growth, Offset By Other Challenges

Jul 13

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Jun 14
Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Jun 10
Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Repligen Stock: Still Quite Overvalued

May 30

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Apr 30
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Apr 15
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Feb 13
At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Jan 08
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Dec 19
Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Nov 01
What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Oct 17
Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Sep 29
Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Aug 09
Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Jul 17
Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

Jul 03
Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Jun 19
With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

May 23
Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Apr 11
Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

Mar 28
Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Mar 08
We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Feb 20
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:RGEN - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20268251011611967
12/31/20257096810617112
12/31/2024627276314213
6/30/2024602-2119155N/A
3/31/202460715110147N/A
12/31/20236394275114N/A
9/30/202367011697147N/A
6/30/202372913851149N/A
3/31/202377816846160N/A
12/31/202280218639172N/A
9/30/202280116615160N/A
6/30/202277915941141N/A
3/31/202273414642133N/A
12/31/202167112848119N/A
9/30/20215931193584N/A
6/30/20215091004083N/A
3/31/2021433803262N/A
12/31/2020366603663N/A
9/30/2020327444465N/A
6/30/2020302314266N/A
3/31/2020286234367N/A
12/31/2019270214467N/A
9/30/2019253233455N/A
6/30/2019233273453N/A
3/31/2019210212541N/A
12/31/2018194171933N/A
9/30/2018184233242N/A
6/30/2018171231421N/A
3/31/201815529N/A18N/A
12/31/201714128N/A17N/A
9/30/201712521N/A4N/A
6/30/201711318N/A5N/A
3/31/201711013N/A12N/A
12/31/201610512N/A8N/A
9/30/20161007N/A9N/A
6/30/2016968N/A17N/A
3/31/2016888N/A14N/A
12/31/2015849N/A15N/A
9/30/2015789N/A13N/A
6/30/2015748N/A13N/A
3/31/2015687N/A8N/A
12/31/2014648N/A18N/A
9/30/20146312N/A24N/A
6/30/20146616N/A24N/A
3/31/20146818N/A30N/A
12/31/20136816N/A26N/A
9/30/20137222N/A26N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: RGEN devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.5% ).

Bénéfices vs marché: RGEN devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: RGEN devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de RGEN ( 13.8% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de RGEN ( 13.8% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de RGEN devrait être faible dans 3 ans ( 4.9 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y